UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Form 6-K

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~November~~December 2015

Commission File Number: 001-33623

WuXi PharmaTech (Cayman) Inc.

288 Fute Zhong Road, Waigaoqiao Free Trade Zone

Shanghai 200131

People’s Republic of China

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ¨ No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82- N/A

WuXi PharmaTech (Cayman) Inc.

Form 6-K

TABLE OF CONTENTS

	Page
Signature		3
Exhibit 99.1 — Press Release, dated November 25, 2015		4
Exhibit 99.1 — Press Release, dated December 10, 2015		4

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


WuXi PharmaTech (Cayman) Inc.

By:		/s/ Edward Hu
Name:		Edward Hu
Title:		Chief Financial Officer

Date: ~~November~~December 2510, 2015

Exhibit 99.1

WuXi PharmaTech (Cayman) Inc. Announces

~~Announces~~Completion ~~Shareholders’~~of ~~Approval~~Going OfPrivate ~~Merger~~Transaction ~~Agreement~~

SHANGHAI, ~~November~~December 2510, 2015 — WuXi PharmaTech (Cayman) Inc. (~~“WuXi” or the “Company”) (~~NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced ~~that~~the atcompletion anof ~~extraordinary~~its ~~general~~merger ~~meeting~~(the of“Merger”) ~~shareholders~~with ~~held~~WuXi ~~today, the~~Merger ~~Company’s~~Limited ~~shareholders~~(“Merger ~~voted~~Sub”), ina wholly-owned ~~favor~~subsidiary of ~~the~~New ~~proposal~~WuXi toLife ~~authorize~~Science ~~and~~Limited ~~approve~~(“Parent”), pursuant to the previously announced ~~agreement~~Agreement and ~~plan~~Plan of ~~merger~~Merger (the “Merger Agreement”), dated as of August 14, 2015 and amended on October 20, ~~2015~~ 2015 and November 20, 2015, ~~with~~among ~~New~~the ~~WuXi~~Company, ~~Life Science Limited (“~~Parent”) and ~~WuXi~~ Merger ~~Limited,~~Sub. As a ~~wholly~~result ~~owned subsidiary~~ of ~~Parent~~the (“Merger ~~Sub”)~~, ~~pursuant~~Parent tohas ~~which~~acquired ~~Merger Sub will be merged with and into~~ the Company ~~with~~(which ~~the Company~~is ~~surviving~~now as a direct wholly owned subsidiary of Parent ~~(the “Merger”~~), ~~and~~in toa ~~authorize~~cash ~~and~~transaction ~~approve~~valued ~~any~~at ~~and~~approximately ~~all transactions contemplated by the Merger Agreement, including the Merger~~US$3.3 billion.

~~426,965,520~~Under ~~ordinary~~the ~~shares~~terms ~~(including~~of ~~ordinary~~the ~~shares~~Merger ~~represented~~Agreement, which was approved by the Company’s ~~American~~shareholders ~~depositary~~at ~~shares,~~an orextraordinary ~~“ADSs”~~general meeting held on November 25, ~~each~~2015, all of ~~which represents~~the ~~eight~~Company’s ordinary shares) ~~were~~(each, ~~voted~~a in“Share”) ~~person~~(including orordinary byshares ~~proxy~~represented atby ~~today’s~~American ~~extraordinary~~Depositary ~~general~~Shares ~~meeting~~(“ADSs”), each representing ~~approximately~~eight ~~75.17%~~Shares) ofissued and outstanding immediately prior to the ~~Company’s~~effective ~~total~~time ~~outstanding~~of ~~ordinary~~the ~~shares~~Merger ~~entitled~~have tobeen ~~vote~~cancelled atin exchange for the ~~extraordinary~~right ~~general meeting.~~to Ofreceive ~~those~~US$5.75 ~~ordinary~~per ~~shares,~~Share ~~approximately~~or 97US$46.~~49%~~00 ~~were~~per ~~voted~~ADS, in ~~favor~~each ofcase, ~~the~~in ~~proposal~~cash, towithout ~~authorize~~interest and ~~approve~~net ~~the~~of ~~Merger~~any ~~Agreement~~applicable ~~and~~withholding ~~any~~taxes, ~~and~~except ~~all~~for ~~transactions~~1,177,079 ~~contemplated~~ADSs held by ~~the~~Hillhouse ~~Merger~~Capital ~~Agreement~~Fund II, ~~including~~L.P., ~~the~~651,892 ~~Merger~~Shares and 49,514 ADSs held by Mr. Xiaozhong ~~The~~Liu, ~~proposal~~executive tovice ~~adopt~~ president and a director of the ~~Merger~~Company, ~~Agreement~~and ~~was~~5,778,304 ~~also~~Shares ~~approved~~held by 97Mr.~~33%~~ Zhaohui Zhang, senior vice president of ~~ordinary~~operations, head ~~shares~~of ~~present~~domestic marketing and ~~voting~~a indirector ~~person~~of orthe byCompany, ~~proxy~~any atShares held by Parent, the ~~extraordinary~~Company ~~general~~or ~~meeting~~any of their subsidiaries, and any Shares (including Shares represented by ADSs) held by ~~holders~~the ~~that~~ADS ~~are~~depositary ~~unaffiliated~~and ~~with~~reserved for issuance and allocation pursuant to the ~~buyer~~Company’s ~~group~~2007 Employee Share Incentive Plan, ~~satisfying~~in each case issued and outstanding immediately prior to the ~~“majority~~effective time of the Merger, which were cancelled without payment of any consideration or distribution therefor. No ~~minority”~~shareholders ~~voting~~validly ~~requirement~~exercised ~~set~~any ~~forth~~dissenters’ inrights ~~the~~under ~~Merger~~Cayman ~~Agreement~~Islands law.

~~The~~Shareholders ~~parties~~of ~~currently~~record ~~expect~~as toof ~~complete~~ the ~~Merger~~effective ~~next~~time ~~month, subject to the satisfaction or waiver~~ of the ~~conditions set forth in the~~ Merger ~~Agreement.~~who are Ifentitled ~~and~~to ~~when completed,~~ the ~~Merger~~merger ~~would~~consideration ~~result~~will inreceive ~~the Company becoming~~ a ~~privately-held~~letter ~~company~~of transmittal and ~~its~~instructions ~~ADSs~~on ~~would~~how noto ~~longer~~surrender betheir ~~listed~~ordinary onshare ~~the~~certificates ~~New~~in ~~York~~exchange ~~Stock~~for ~~Exchange. In addition,~~ the ~~ADSs~~merger ~~and~~consideration. ~~the~~Shareholders ~~Company’s~~should ~~ordinary~~wait ~~shares~~to ~~represented~~receive by the ~~ADSs~~letter ~~will cease to be registered under Section 12~~ of transmittal ~~the~~before ~~Securities~~surrendering ~~Exchange~~their ~~Act~~ordinary ofshare ~~1934~~certificates.

~~Cautionary~~ADS ~~Statement~~holders of record as of the effective time of the Merger who are entitled to the merger consideration will automatically receive from JPMorgan Chase Bank, N.A., the Company’s ADS depositary, US$46.00 per each ADS held by them (less an ADS cancellation fee of US$0.05 per ADS) in cash, without interest and net of any applicable withholding taxes, in exchange for the cancellation of such ADSs. Payment of the ADS merger consideration will be made to such ADS holders as soon as practicable after the Company’s ADS depositary receives the merger consideration. ADS holders which hold their ADSs in “street name” through their broker, bank or other nominee will not be required to take any action to receive the net ADS merger consideration for their ADSs as the Company’s ADS depositary will arrange for the surrender of such ADSs and the remittance of the per ADS merger consideration with The Depository Trust Company (the clearance and settlement system for the ADSs) for distribution to the applicable broker, bank or nominee on behalf of such beneficial owners. Any questions concerning ~~Forward~~the ~~Looking~~receipt ~~Statements~~of the per ADS merger consideration from holders who hold ADSs in “street name” should be directed by such holders to their applicable broker, bank or nominee.

~~This~~The ~~document~~Company ~~may~~also ~~include~~announced ~~certain~~today ~~statements~~ that ~~are~~it ~~not~~requested ~~descriptions~~that trading of ~~historical~~its ~~facts,~~ADSs ~~but~~on ~~are~~the ~~forward-looking~~New ~~statements.~~York ~~Forward-looking~~Stock ~~statements~~Exchange ~~can generally~~(the “NYSE”) be ~~identified~~suspended byas of the ~~use~~ close of ~~forward-looking~~trading ~~terminology~~on ~~such~~December 10, as2015. ~~“will,”~~The ~~“should,”~~Company ~~“may,”~~requested ~~“believes,”~~that ~~“expects”~~the orNYSE ~~similar~~file ~~expressions.~~a ~~Such~~Form ~~statements~~25 ~~include,~~with ~~among~~the ~~others,~~Securities ~~those concerning~~and Exchange Commission (the ~~expected~~“SEC”) ~~timing~~notifying the SEC of the ~~completion~~delisting of ~~the~~its ~~Merger;~~ADSs on the ~~possibility~~NYSE ~~that~~and ~~various~~the ~~closing~~deregistration ~~conditions~~of ~~for~~ the Company’s ~~Merger~~registered ~~may~~securities. ~~not~~The bederegistration ~~satisfied~~will orbecome ~~waived~~effective ~~and~~90 ~~the~~days ~~Merger~~after ~~may~~the ~~not~~filing ~~occur~~of ~~and~~the ~~other~~Form ~~risks~~25 ~~and~~or ~~uncertainties~~such ~~discussed~~shorter inperiod ~~documents~~as ~~filed with~~may ~~the~~be ~~SEC~~determined by the ~~Company,~~SEC. asThe ~~well~~Company asintends ~~the~~to ~~Schedule~~suspend ~~13E-3~~its ~~transaction~~reporting ~~statement~~obligations ~~and~~under the Securities ~~proxy~~Exchange ~~statement~~Act ~~filed~~of by1934, ~~the~~as ~~Company.~~amended, ~~All~~by offiling ~~such~~a ~~assumptions~~Form ~~are~~15 ~~inherently~~with ~~subject~~the toSEC ~~uncertainties~~in ~~and~~approximately ~~contingencies~~ten ~~beyond~~days. ~~the~~The Company’s ~~control~~obligations ~~and based~~to ~~upon~~file ~~premises~~ with ~~respect~~the toSEC ~~future~~certain ~~business~~reports ~~decisions~~and forms, ~~which~~including ~~are~~Form ~~subject~~20-F toand ~~change.~~Form ~~The~~6-K, ~~Company~~will ~~does~~be ~~not~~suspended ~~undertake~~immediately as ~~any~~of ~~obligation~~the tofiling ~~update~~date ~~any~~of ~~forward-looking~~the ~~statement,~~Form ~~except~~15 asand ~~required~~will ~~under~~cease ~~applicable~~once ~~law~~the deregistration becomes effective.

About WuXi PharmaTech

WuXi PharmaTech (NYSE: WX) is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech’s services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For further information, please visit http://www.wuxiapptec.com.

Cautionary Statement Concerning Forward Looking Statements

This document may include certain statements that are not descriptions of historical facts, but are forward-looking statements. Forward-looking statements can generally be identified by the use of forward-looking terminology such as “will,” “should,” “may,” “believes,” “expects” or similar expressions. All of such assumptions are inherently subject to uncertainties and contingencies beyond the Company’s control and based upon premises with respect to future business decisions, which are subject to change. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

About WuXi PharmaTech

For more information, please contact:

Ronald Aldridge (for investors)

~~LaVoieHealthScience~~LaVoie HealthScience

+1 -617-374-8800 x109

+1 617-792-2459

~~ron_aldridge~~ir@wuxiapptec.com

Aaron Shi (for the media)

Director, Corporate Communications

WuXi PharmaTech

+86-21-5046-4362

~~aaron_shi~~pr@wuxiapptec.com

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Filing Compare · WuXi PharmaTech (Cayman) Inc.